The melanoma cohort of REFINE has opened to participants. The REFINE trial is looking at whether giving immunotherapy less often is as effective at treating advanced cancer than the current treatment. It will look initially at patients with kidney (renal) and melanoma cancers. Immunotherapy is a type of cancer treatment that uses drugs called checkpoint inhibitors. Checkp ...
The REFINE Trial is presented at the European Society for Medical Oncology Congress
Sophie Merrick presented the REFINE trial at the European Society for Medical Oncology (ESMO) Congress in Paris on the 12th September. The REFINE trial is testing different time intervals of treatment using checkpoint inhibitors, to treat different types of cancers (renal, melanoma and colorectal). The REFINE renal cancer cohort opened to recruitment on the 25th May 2022 an ...
First patient recruited into REFINE
REFINE recruited its first patient on 22/08/2022.